Breast Cancer, Colon Cancer, Prostate Cancer
Conditions
Brief summary
The aim of this study was to determine the kinetics of perioperative circulating DNA in three types of cancer. This first step will enable further studies comparing the potential impact of certain techniques or anesthetic products on cancer surgery.
Interventions
OTHERBlood test
plasma concentration of circulating DNA of specific genes
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* The patient must have given their free and informed consent and signed the consent form * The patient must be a member or beneficiary of a health insurance plan * The patient is aged between 18-75 * Patient must weigh \>40kg * The patient will receive adjusted carcinological surgery * Indication of curative surgery * The patient has already undergone tumoral biopsy prior to surgery * The patient has stage M0 cancer of either colon (right or left colonic adenocarcinoma), prostate (adenocarcinoma) or breast (infiltrating carcinoma)
Exclusion criteria
* The subject is in a period of exclusion determined by a previous study * The patient is under safeguard of justice * The subject refuses to sign the consent * It is impossible to give the subject informed information * The patient is pregnant, parturient or breast feeding * Chronic alcoholism * The patient has received radiotherapy or chemotherapy periopratively * Cancer other than colon, breast or prostate * The patient has currently or in the past, had a cancerous lesion * Neo-adjuvant therapy (immunotherapy, radiotherapy, chemotherapy) * Emergency cancer surgery
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in concentration of total mutant circulating DNA | Nine timepoints between Day-1 to Day 3 | ng/mL in plasma |
| Change in proportion of mutant circulating DNA | Nine timepoints between Day-1 to Day 3 | ng/mL in plasma |
| Change in integrity index of circulating DNA for ACTB gene | Nine timepoints between Day-1 to Day 3 | concentration of long ACTB ctDNA fragments/concentration of short ACTB ctDNA fragments |
| Change in integrity index of circulating DNA for KRAS gene | Nine timepoints between Day-1 to Day 3 | concentration of long KRAS ctDNA fragments/concentration of short KRAS ctDNA fragments |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in plasma concentration of long (~ 290bp) fragments of ACTB gene | Nine timepoints between Day-1 to Day 3 | ng/mL in plasma |
| Change in plasma concentration of BRAF DNA fragments with V600E mutation | Nine timepoints between Day-1 to Day 3 | ng/mL in plasma |
| Change in plasma concentration of short (~ 145bp) fragments of KRAS gene | Nine timepoints between Day-1 to Day 3 | ng/mL in plasma |
| Change in plasma concentration of long (~ 300bp) fragments of KRAS gene | Nine timepoints between Day-1 to Day 3 | ng/mL in plasma |
| Change in plasma concentration of mutant KRAS DNA fragments | Nine timepoints between Day-1 to Day 3 | ng/mL in plasma |
Countries
France
Outcome results
None listed